

Electronic Acknowledgement Receipt

EFS ID:	3386584
Application Number:	10572670
International Application Number:	
Confirmation Number:	4600
Title of Invention:	Polymorphic form of 3-phenylsulfonyl -8-piperazin-1-yl-quinoline
First Named Inventor/Applicant Name:	Asa Elisabeth Gladwin
Customer Number:	20462
Filer:	Kathryn Lutomski Sieburth/Audrey Boyd
Filer Authorized By:	Kathryn Lutomski Sieburth
Attorney Docket Number:	PB60517
Receipt Date:	02-JUN-2008
Filing Date:	20-MAR-2006
Time Stamp:	10:55:39
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$300
RAM confirmation Number	6613
Deposit Account	192570
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1		ROA_2_13_08.pdf	806444	yes	16
			893e174953d3c5d68d15b60b3da37b35ade471b1		

	Multipart Description/PDF files in .zip description			
	Document Description		Start	End
	Amendment - After Non-Final Rejection		1	1
	Abstract		2	2
	Specification		3	3
	Claims		4	7
	Applicant Arguments/Remarks Made in an Amendment		8	14
	Drawings-only black and white line drawings		15	15
	Abstract		16	16

Warnings:

Information:

2	Information Disclosure Statement Letter	IDS_w_Fee.pdf	63309	no	2
			10e0ef5cee70b60ebd5ec2194cdda92eeef1675		

Warnings:

Information:

3	Information Disclosure Statement (IDS) Filed	PTO_1449.pdf	112857	no	1
			9dca6f121379b9502b62197ce2adee63e1b0371b		

Warnings:

Information:

This is not an USPTO supplied IDS fillable form

4	Foreign Reference	1WO2003035061A1.pdf	947044	no	32
			545c3e6a7498b0b4476ab3e0db678c50ffdb322		

Warnings:

Information:					
5	Foreign Reference	2WO2003066056A1.pdf	1031391	no	21
			7a291a6ed63fab213363c8b26e9e6fc5e89a9905		
Warnings:					
Information:					
6	NPL Documents	3Woolley_Neuropharm_2001.pdf	258731	no	10
			a3da374db2022aebb876e0ac016a75a97c878fa1		
Warnings:					
Information:					
7	NPL Documents	4Mitchell_Pharmacol_Ther_2005.pdf	2006749	no	14
			bef175af9cda3e5223980207e48aa3e87df2571f		
Warnings:					
Information:					
8	NPL Documents	5Chuang_Alz_Dementia.pdf	594503	no	5
			46cd44df01863511da3cf7f48e7ce3032b853fb6		
Warnings:					
Information:					
9	NPL Documents	6London_SE_Announcement_2007.pdf	329366	no	4
			def948c4359285abd08c9c5229789d78824f0329		
Warnings:					
Information:					
10	NPL Documents	7Dose_Ranging_Study_SB742457_2007.pdf	131689	no	4
			d80312d045ab9d0de103debc675d0da4bdb25690		
Warnings:					
Information:					
11	NPL Documents	8SB742457_Donepezil_AD_2006.pdf	130389	no	4
			25a590b567b9187a2bbec1602c83287847dc21b4		
Warnings:					
Information:					
12	NPL Documents	9Garcia_Alloza_Neuropsychopharm_2004.pdf	1039342	no	7
			e068789af8d0f5dd513dd8a4764f76c4f7438ccf		
Warnings:					
Information:					
13	Fee Worksheet (PTO-06)	fee-info.pdf	8359	no	2
			e368b5ae3c388eca849a8e677994d8c1ee8a9724		
Warnings:					

Information:	
Total Files Size (in bytes):	7460173
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>	